187 related articles for article (PubMed ID: 36674662)
1. β3 Adrenergic Receptor Agonist Mirabegron Increases AQP2 and NKCC2 Urinary Excretion in OAB Patients: A Pleiotropic Effect of Interest for Patients with X-Linked Nephrogenic Diabetes Insipidus.
Milano S; Maqoud F; Rutigliano M; Saponara I; Carmosino M; Gerbino A; Lucarelli G; Battaglia M; Svelto M; Procino G
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674662
[TBL] [Abstract][Full Text] [Related]
2. The β3-AR agonist BRL37344 ameliorates the main symptoms of X-linked nephrogenic diabetes insipidus in the mouse model of the disease.
Milano S; Saponara I; Gerbino A; Carmosino M; Svelto M; Procino G
J Cell Mol Med; 2024 Apr; 28(8):e18301. PubMed ID: 38652212
[TBL] [Abstract][Full Text] [Related]
3. Human β3-Adrenoreceptor is Resistant to Agonist-Induced Desensitization in Renal Epithelial Cells.
Milano S; Gerbino A; Schena G; Carmosino M; Svelto M; Procino G
Cell Physiol Biochem; 2018; 48(2):847-862. PubMed ID: 30032151
[TBL] [Abstract][Full Text] [Related]
4. Hereditary Nephrogenic Diabetes Insipidus: Pathophysiology and Possible Treatment. An Update.
Milano S; Carmosino M; Gerbino A; Svelto M; Procino G
Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29125546
[TBL] [Abstract][Full Text] [Related]
5. Treating lithium-induced nephrogenic diabetes insipidus with a COX-2 inhibitor improves polyuria via upregulation of AQP2 and NKCC2.
Kim GH; Choi NW; Jung JY; Song JH; Lee CH; Kang CM; Knepper MA
Am J Physiol Renal Physiol; 2008 Apr; 294(4):F702-9. PubMed ID: 18216147
[TBL] [Abstract][Full Text] [Related]
6. Novel mutations associated with nephrogenic diabetes insipidus. A clinical-genetic study.
García Castaño A; Pérez de Nanclares G; Madariaga L; Aguirre M; Chocron S; Madrid A; Lafita Tejedor FJ; Gil Campos M; Sánchez Del Pozo J; Ruiz Cano R; Espino M; Gomez Vida JM; Santos F; García Nieto VM; Loza R; Rodríguez LM; Hidalgo Barquero E; Printza N; Camacho JA; Castaño L; Ariceta G;
Eur J Pediatr; 2015 Oct; 174(10):1373-85. PubMed ID: 25902753
[TBL] [Abstract][Full Text] [Related]
7. AQP2: Mutations Associated with Congenital Nephrogenic Diabetes Insipidus and Regulation by Post-Translational Modifications and Protein-Protein Interactions.
Gao C; Higgins PJ; Zhang W
Cells; 2020 Sep; 9(10):. PubMed ID: 32993088
[TBL] [Abstract][Full Text] [Related]
8. Genetic forms of nephrogenic diabetes insipidus (NDI): Vasopressin receptor defect (X-linked) and aquaporin defect (autosomal recessive and dominant).
Bichet DG; Bockenhauer D
Best Pract Res Clin Endocrinol Metab; 2016 Mar; 30(2):263-76. PubMed ID: 27156763
[TBL] [Abstract][Full Text] [Related]
9. Fluconazole Increases Osmotic Water Transport in Renal Collecting Duct through Effects on Aquaporin-2 Trafficking.
Vukićević T; Hinze C; Baltzer S; Himmerkus N; Quintanova C; Zühlke K; Compton F; Ahlborn R; Dema A; Eichhorst J; Wiesner B; Bleich M; Schmidt-Ott KM; Klussmann E
J Am Soc Nephrol; 2019 May; 30(5):795-810. PubMed ID: 30988011
[TBL] [Abstract][Full Text] [Related]
10. β3 adrenergic receptor in the kidney may be a new player in sympathetic regulation of renal function.
Procino G; Carmosino M; Milano S; Dal Monte M; Schena G; Mastrodonato M; Gerbino A; Bagnoli P; Svelto M
Kidney Int; 2016 Sep; 90(3):555-67. PubMed ID: 27206969
[TBL] [Abstract][Full Text] [Related]
11. Genetic basis of nephrogenic diabetes insipidus.
Hureaux M; Vargas-Poussou R
Mol Cell Endocrinol; 2023 Jan; 560():111825. PubMed ID: 36460218
[TBL] [Abstract][Full Text] [Related]
12. Combination of secretin and fluvastatin ameliorates the polyuria associated with X-linked nephrogenic diabetes insipidus in mice.
Procino G; Milano S; Carmosino M; Barbieri C; Nicoletti MC; Li JH; Wess J; Svelto M
Kidney Int; 2014 Jul; 86(1):127-38. PubMed ID: 24522493
[TBL] [Abstract][Full Text] [Related]
13. Activation of AQP2 water channels by protein kinase A: therapeutic strategies for congenital nephrogenic diabetes insipidus.
Ando F
Clin Exp Nephrol; 2021 Oct; 25(10):1051-1056. PubMed ID: 34224008
[TBL] [Abstract][Full Text] [Related]
14. Vasopressin-independent targeting of aquaporin-2 by selective E-prostanoid receptor agonists alleviates nephrogenic diabetes insipidus.
Olesen ET; Rützler MR; Moeller HB; Praetorius HA; Fenton RA
Proc Natl Acad Sci U S A; 2011 Aug; 108(31):12949-54. PubMed ID: 21768374
[TBL] [Abstract][Full Text] [Related]
15. Genetic analysis of nephrogenic diabetes insipidus patients: A study on the Iranian population.
Ghasemi S; Mojbafan M; Talebi S; Hooman N; Hoseini R
Mol Genet Genomic Med; 2024 Apr; 12(4):e2421. PubMed ID: 38622833
[TBL] [Abstract][Full Text] [Related]
16. Correlation between AVPR2 mutations and urinary AQP2 excretion in patients with nephrogenic diabetes insipidus.
Kotnik P; Battelino T; Debeljak M; Podkrajsek KT; Waldhauser F; Frøkiaer J; Nielsen S; Krzisnik C
J Pediatr Endocrinol Metab; 2007 Apr; 20(4):483-9. PubMed ID: 17550212
[TBL] [Abstract][Full Text] [Related]
17. [Family form of nephrogenic X-linked diabetes indiabetes].
Klepalova VV; Pushkareva OS; Iziurova NV; Aksenov AV
Probl Endokrinol (Mosk); 2022 Jul; 68(5):87-90. PubMed ID: 36337022
[TBL] [Abstract][Full Text] [Related]
18. Activation of AQP2 water channels without vasopressin: therapeutic strategies for congenital nephrogenic diabetes insipidus.
Ando F; Uchida S
Clin Exp Nephrol; 2018 Jun; 22(3):501-507. PubMed ID: 29478202
[TBL] [Abstract][Full Text] [Related]
19. Novel mutation of aquaporin-2 gene in a patient with congenital nephrogenic diabetes insipidus.
Moon SS; Kim HJ; Choi YK; Seo HA; Jeon JH; Lee JE; Lee JY; Kwon TH; Kim JG; Kim BW; Lee IK
Endocr J; 2009; 56(7):905-10. PubMed ID: 19461158
[TBL] [Abstract][Full Text] [Related]
20. [Vasopressin V2 receptor-related pathologies: congenital nephrogenic diabetes insipidus and nephrogenic syndrome of inappropiate antidiuresis].
Morin D
Nephrol Ther; 2014 Dec; 10(7):538-46. PubMed ID: 25449762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
